Sara Barmettler1, Iris M Otani2,3, Jasmit Minhas4, Roshini S Abraham5, Yenhui Chang6, Morna J Dorsey3, Zuhair K Ballas7, Francisco A Bonilla8, Hans D Ochs9, Jolan E Walter2,6. 1. Massachusetts General Hospital, Boston, MA, USA. sbarmettler@mgh.harvard.edu. 2. Massachusetts General Hospital, Boston, MA, USA. 3. University of San Francisco, San Francisco, CA, USA. 4. Lahey Hospital & Medical Center, Burlington, MA, USA. 5. Mayo Clinic, Rochester, MN, USA. 6. University of South Florida at Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA. 7. University of Iowa Hospitals and Clinic, Iowa City, IA, USA. 8. Boston Children's Hospital, Boston, MA, USA. 9. Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, USA.
Abstract
PURPOSE: X-linked agammaglobulinemia is a primary humoral immunodeficiency characterized by hypogammaglobulinemia and increased susceptibility to infection. Although there is increased awareness of autoimmune and inflammatory complications in X-linked agammaglobulinemia (XLA), the spectrum of gastrointestinal manifestations has not previously been fully explored. METHODS: We present a case report of a family with two affected patients with XLA. Given the gastrointestinal involvement of the grandfather in this family, we performed a retrospective descriptive analysis of XLA patients with reported diagnoses of GI manifestations and inflammatory bowel disease (IBD) or enteritis registered at the United States Immunodeficiency Network, a national registry of primary immunodeficiencies. RESULTS: In this cohort of patients with XLA, we found that up to 35% had concurrent gastrointestinal manifestations, and 10% had reported diagnoses of IBD or enteritis. The most commonly reported mutations were missense, which have been associated with a less severe XLA phenotype in the literature. The severity of symptoms were wide ranging, and management strategies were diverse and mainly experimental. CONCLUSIONS: Patients with XLA may require close monitoring with particular attention for GI manifestations including IBD and infectious enteritis. Further studies are needed to improve diagnosis and management of GI conditions in XLA patients.
PURPOSE:X-linked agammaglobulinemia is a primary humoral immunodeficiency characterized by hypogammaglobulinemia and increased susceptibility to infection. Although there is increased awareness of autoimmune and inflammatory complications in X-linked agammaglobulinemia (XLA), the spectrum of gastrointestinal manifestations has not previously been fully explored. METHODS: We present a case report of a family with two affected patients with XLA. Given the gastrointestinal involvement of the grandfather in this family, we performed a retrospective descriptive analysis of XLApatients with reported diagnoses of GI manifestations and inflammatory bowel disease (IBD) or enteritis registered at the United States Immunodeficiency Network, a national registry of primary immunodeficiencies. RESULTS: In this cohort of patients with XLA, we found that up to 35% had concurrent gastrointestinal manifestations, and 10% had reported diagnoses of IBD or enteritis. The most commonly reported mutations were missense, which have been associated with a less severe XLA phenotype in the literature. The severity of symptoms were wide ranging, and management strategies were diverse and mainly experimental. CONCLUSIONS:Patients with XLA may require close monitoring with particular attention for GI manifestations including IBD and infectious enteritis. Further studies are needed to improve diagnosis and management of GI conditions in XLApatients.
Authors: Vivian P Hernandez-Trujillo; Chris Scalchunes; Charlotte Cunningham-Rundles; Hans D Ochs; Francisco A Bonilla; Ken Paris; Leman Yel; Kathleen E Sullivan Journal: J Clin Immunol Date: 2014-06-10 Impact factor: 8.317
Authors: Holm H Uhlig; Tobias Schwerd; Sibylle Koletzko; Neil Shah; Jochen Kammermeier; Abdul Elkadri; Jodie Ouahed; David C Wilson; Simon P Travis; Dan Turner; Christoph Klein; Scott B Snapper; Aleixo M Muise Journal: Gastroenterology Date: 2014-07-21 Impact factor: 33.883
Authors: Cristiane J Nunes-Santos; Christopher Koh; Anjali Rai; Keith Sacco; Beatriz E Marciano; David E Kleiner; Jamie Marko; Jenna R E Bergerson; Michael Stack; Maria M Rivera; Gregory Constantine; Warren Strober; Gulbu Uzel; Ivan J Fuss; Luigi D Notarangelo; Steven M Holland; Sergio D Rosenzweig; Theo Heller Journal: J Allergy Clin Immunol Date: 2021-06-01 Impact factor: 10.793
Authors: Jeroen D Langereis; Stefanie S Henriet; Saskia Kuipers; Corry M R Weemaes; Mirjam van der Burg; Marien I de Jonge; Michiel van der Flier Journal: J Clin Immunol Date: 2018-01-15 Impact factor: 8.317